文献速递胸部病理细胞病理与分子病理

肺结节联合FNA与CNB的诊断效能及分子检测

Diagnostic efficacy and molecular testing by combined fine-needle aspiration and core needle biopsy in patients with a lung nodule.
PubMed 文献 · Cancer Cytopathol · 2020-01-08

该研究纳入2012年667例患者共682次联合肺FNA/CNB操作,评估联合活检的诊断效能。结果显示联合FNA/CNB对恶性肿瘤诊断准确率98.5%,灵敏度97.6%,特异度100%,假阴性率2.2%低于单独FNA(7.2%)或CNB(6.2%)。FNA作为补充组织来源贡献了10.3%的分子分析。

要点

  • 联合FNA/CNB对肺结节恶性诊断准确率98.5%,灵敏度97.6%,特异度100%。
  • 联合FNA/CNB假阴性率2.2%,低于单独FNA的7.2%或CNB的6.2%。
  • FNA作为补充组织来源贡献了10.3%的分子分析。

核心结论

  • 联合肺FNA/CNB对恶性肿瘤具有高诊断效能,且假阴性率低于单独FNA或CNB。
  • FNA是CNB用于分子检测的有价值补充,可能减少重复肺穿刺活检带来的不便和并发症。

研究设计与样本

  • 回顾性研究,纳入2012年单中心667例患者共682次联合肺FNA/CNB操作,其中男性355例、女性312例。
  • 联合操作由放射科医师执行,FNA标本由细胞病理医师即时评估 adequacy,FNA和CNB标本分别由细胞病理医师和外科病理医师独立判读。

主要发现

  • FNA与CNB诊断一致率为83.4%。
  • 联合FNA/CNB对恶性肿瘤诊断准确率为98.5%。
  • 联合FNA/CNB对恶性肿瘤灵敏度97.6%、特异度100%。
  • 联合FNA/CNB假阴性率2.2%,单独FNA为7.2%,单独CNB为6.2%。
  • FNA贡献了10.3%的分子分析作为补充组织来源。

临床怎么用

  • 对肺结节患者采用联合FNA/CNB可提高恶性诊断准确率并降低假阴性率。
  • FNA标本可作为CNB的补充用于分子检测,有助于避免重复活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combined image-guided fine-needle aspiration biopsy (FNA) and core needle biopsy (CNB) has become the standard of care for diagnosis and/or molecular testing for patients with a solitary lung nodule at our institution. Our purpose was to evaluate the efficacy of this practice. METHODS: We identified patients who underwent combined lung FNA/CNB during 2012 at our institution. A total of 667 patients who underwent 682 combined lung FNA/CNB procedures were included in the study, including 355 men and 312 women. Combined lung FNA/CNB procedures were performed by a radiologist. The adequacy of FNA specimens was assessed immediately by a cytopathologist. The FNA and CNB specimens were interpreted separately by a cytopathologist and a surgical pathologist, respectively. The diagnostic accuracy of the combined technique was determined. RESULTS: The rate of diagnostic consistency between FNA and CNB was 83.4%, and the rate of diagnostic accuracy for malignancy was 98.5% for combined FNA/CNB. Combined FNA/CNB showed a high diagnostic efficacy for malignancy (sensitivity, 97.6%; specificity, 100%). Combined FNA/CNB had a lower false-negative rate for malignancy (2.2%) than either FNA (7.2%) or CNB (6.2%) alone. FNA contributed to 10.3% of molecular analyses as a complementary tissue source. CONCLUSIONS: Combined lung FNA/CNB has high diagnostic efficacy for malignancy and a lower false-negative rate than either procedure alone. FNA was a valuable complement to CNB for molecular testing, potentially reducing patient inconvenience and morbidity associated with repeated lung needle biopsy.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Chen L, Jing H, Gong Y, et al. Diagnostic efficacy and molecular testing by combined fine-needle aspiration and core needle biopsy in patients with a lung nodule. Cancer Cytopathol. 2020. PMID: 31913583. doi:10.1002/cncy.22234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。